/** blogpostTitle: IOL Chemicals Q1 FY27: Volume-led rebound, non-ibuprofen APIs gain share blogpostSlug: iol-q1 blogpostCoverImageUrl: null blogpostCoverImageDescription: Ultra-realistic corporate finance scene showing a clean desk with a laptop displaying two side-by-side line charts: one chart for quarterly revenue rising sharply to 756.3 (INR crore) and another for EBITDA margin rising to 14.6%. In the background, a subtle split view of a pharmaceutical reactor vessel and a chemical distillation column to represent the two segments. Neutral office lighting, no logos, no text labels. blogpostShortTitle: IOL Chemicals Q1 FY27 performance snapshot */

IOL Chemicals Q1 FY27: Volume-led rebound, non-ibuprofen APIs gain share

IOL Chemicals and Pharmaceuticals Limited opened FY27 with a strong quarter. Standalone revenue from operations rose to INR756.3 crore in Q1 FY27, up 37.1% year on year. Profitability improved faster than revenue. EBITDA came in at INR111.7 crore, up 60.7%, with an EBITDA margin of 14.6%. PAT rose to INR64.5 crore, up 89.9%, and PAT margin improved to 8.4%.

Management attributed the jump to higher capacity utilisation, better operating leverage, and product mix improvement. The call also highlighted a healthier contribution from non-ibuprofen APIs and a higher export share.

Segment performance: Pharma leads, chemicals add support

Pharmaceuticals drove the quarter. Segment revenue rose to INR469.5 crore in Q1 FY27 versus INR329.3 crore in Q1 FY26, while EBIT increased to INR68.8 crore from INR40.1 crore. The quarter also showed sequential improvement versus Q4 FY26, when pharma revenue was INR374.5 crore and EBIT was INR62.2 crore.

Specialty chemicals also improved. Chemicals revenue net of intersegment stood at INR286.8 crore in Q1 FY27 versus INR222.4 crore in Q1 FY26. Segment EBIT rose to INR17.3 crore from INR5.9 crore a year ago.

Geographically, exports formed 29% of revenue in Q1 FY27 as per the investor presentation. On the conference call, management quantified the export contribution at about 28.5% of revenue, up from 24.4% in Q1 FY26.

Diversification beyond ibuprofen: moving from intent to numbers

A central theme in both the presentation and the concall was portfolio diversification. The investor deck shows that ibuprofen contributed 82% of pharma revenue in FY21, but fell to 63% by FY26, with other APIs rising to 37%.

In Q1 FY27, management stated that non-ibuprofen products contributed 43% of pharmaceutical revenue, compared with 36% in Q1 FY26. This is an important marker because it suggests that newer APIs are no longer peripheral. The company identified paracetamol, clopidogrel, pantoprazole, metformin, fenofibrate, and levetiracetam as key growth drivers.

Paracetamol remains the most closely watched ramp. Management said the expanded 10,800 MTPA paracetamol capacity is currently operating at around 55% utilisation and is expected to reach around 70% by the end of FY27. This indicates that volume upside is still expected through utilisation gains, not only through new capacity.

Regulated market access is another lever supporting the strategy. The company highlighted 14 DMFs with USFDA and 21 CEPs with EDQM. On the call, management also mentioned NMPA approval for clopidogrel in China, expanding regulatory reach. They added that some products are lined up where formulators have filed ANDAs, and approvals could translate into additional market access for IOL’s APIs.

Chemicals and new products: pricing steadies, triacetin ramps

The chemicals segment performance improved on better realisations, raw material procurement, exports, and operating efficiency, according to management commentary. Investors asked about the effect of geopolitical events on ethyl acetate and acetic anhydride pricing. Management said prices increased substantially in March but have been stable recently, and they expect the delta between raw material and ethyl acetate to remain broadly constant in upcoming quarters.

The company also discussed triacetin, a newer specialty chemical product with installed capacity of 6,000 MTPA. Management said production started after May, implying only around one month of output in Q1 FY27. The CFO cited a steady-state revenue potential of around INR120 crore per year. Commercial ramp will depend on customer penetration and market development.

Guidance: FY27 targets and capital allocation

IOL reiterated its FY26-27 guidance in both the investor presentation and the concall.

The company guided for 15% to 20% revenue growth, EBITDA margin of 14% to 15%, exports contribution of 25% to 30%, and capex of INR200 to 250 crore.

On capital allocation, management explained that capex is planned with a long-term view, and that around 60% is directed to expansion and new products, while around 40% goes to infrastructure and efficiency improvement.

A longer-term expansion option is the 101-acre land parcel purchased near the existing facility. Management said statutory permissions and clearances are in process, and that activity at the site is likely not in FY27.

Takeaways

Q1 FY27 shows a clear improvement in operating performance, with profitability rising faster than revenue. The quarter’s narrative is strongly volume and utilisation led, supported by a stronger export share and higher contribution from non-ibuprofen APIs.

The key execution variables to watch are the paracetamol utilisation ramp, sustained demand across the broader API portfolio, and the pace at which newer chemical products like triacetin scale. Management has retained FY27 guidance despite the strong quarter, positioning expectations around capacity utilisation, operating efficiency, and export expansion rather than one-off benefits.